Nkarta, Inc.
NKTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001787400
No open-market purchases or sales by Nkarta, Inc. insiders were filed in the last 90 days; 135 institutions reported holding it in 13F filings for Q2 2026, worth $167.9M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Nkarta, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Nkarta, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Hastings Paul J | Chief Executive Officer | 390,247 | Jun 22, 2026 | 3 |
| RA Capital Healthcare Fund LP | Director, 10% Owner | 10,050,818Indirect | Jun 11, 2026 | 1 |
| Ra Capital Management, L.P. | Director, 10% Owner | 10,050,818Indirect | Jun 11, 2026 | 1 |
| Kolchinsky Peter | Director, 10% Owner | 10,050,818Indirect | Jun 11, 2026 | 1 |
| Shah Rajeev M. | Director, 10% Owner | 10,050,818Indirect | Jun 11, 2026 | 1 |
| RA Capital Nexus Fund, L.P. | Director | 10,050,818Indirect | Jun 11, 2026 | 1 |
| Patterson Leone D | Director | – | Jun 11, 2026 | 1 |
| George Simeon | Director | 451,659Indirect | Jun 11, 2026 | 1 |
| Dybbs Michael | Director | – | Jun 11, 2026 | 1 |
| Behbahani Ali | Director | – | Jun 11, 2026 | 1 |
| Thedinga Angela | Director | – | Jun 11, 2026 | 1 |
| Scheiner Zachary | Director | – | Jun 11, 2026 | 1 |
| Vratsanos George | Director | – | Jun 11, 2026 | 1 |
| Mahmood Nadir | President | 167,727 | Jan 20, 2026 | 2 |
| Rose Shawn Marshall | See Remarks | 70,000 | Jan 8, 2026 | 1 |
| Hager Alicia J. | Chief Legal Officer | 146,735 | Jan 17, 2025 | 0 |
| Brandenberger Ralph | Chief Technical Officer | 124,796 | Jan 17, 2025 | 0 |
| Shook David | See Remarks | 190,955 | Jan 17, 2025 | 0 |
| Levin Alyssa | See Remarks | 102,662 | Jan 17, 2025 | 0 |
| Trager James | Chief Scientific Officer | 150,959 | Jun 20, 2024 | 0 |
| Azzam Fouad Oscar | Director | – | Jun 9, 2023 | 0 |
| Shawver Laura | Director | – | Jun 10, 2022 | 0 |
| Aynechi Tiba | Director | – | Jun 10, 2022 | 0 |
| Rajangam Kanya | Chief Medical Officer | 12,800 | Jan 19, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 28, 2022 (view filing)4:32 PM ET | Apr 26 | 2 days | RA Capital Healthcare Fund LP and 4 othersDirector, 10% Owner | PPurchase | +2.20M | $15.00 | +$33.0M | +39.2%7.81M after | |
| Dec 3, 2021 (view filing)5:02 PM ET | Dec 1 | 2 days | Brandenberger RalphSr. VP, Technical Operations | SSale | −4.14K | $15.64 | −$64.7K | −100.0%0 after | |
| Oct 1, 2021 (view filing) | Sep 29 | 2 days | Hastings Paul JChief Executive Officer | SSale | −8.50K | $27.18 | −$231.1K | −3.7%219.1K after | 2 lots |
| Sep 2, 2021 (view filing)8:52 PM ET | Sep 1 | 1 day | Brandenberger RalphSee Remarks | SSale | −4.14K | $32.08 | −$132.8K | −100.0%0 after | |
| Aug 9, 2021 (view filing)5:17 PM ET | Aug 5 | 4 days | Rajangam KanyaChief Medical Officer | SSale | −10.0K | $37.28 | −$372.8K | −100.0%0 after | |
| Aug 4, 2021 (view filing) | Aug 2 | 2 days | Trager JamesChief Scientific Officer | SSale | −3.60K | $31.53 | −$113.5K | −7.5%44.4K after | |
| Jul 6, 2021 (view filing) | Jul 1 | 5 days | Mahmood NadirSee Remarks | SSale | −6.50K | $31.71 | −$206.1K | −19.2%27.3K after |